Stockscreener 앱 받기
22.09
3.66%
0.78
전일 마감가:
$21.31
열려 있는:
$21.21
하루 거래량:
12.69M
Relative Volume:
1.69
시가총액:
$25.03B
수익:
$16.77B
순이익/손실:
$-959.00M
주가수익비율:
-11.04
EPS:
-2
순현금흐름:
$1.37B
1주 성능:
+33.88%
1개월 성능:
+29.71%
6개월 성능:
+29.48%
1년 성능:
+112.20%
1일 변동 폭
$21.11
$22.17
1주일 범위
$16.29
$22.17
52주 변동 폭
$10.34
$22.17
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
My Top 10 Portfolio Holdings for 2025 - The Motley Fool
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Inkl
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Is Kingsoft Cloud (KC) Outperforming Other Computer and Technology Stocks This Year? - Yahoo Finance
Opera Gains 27% in 3 Months: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - Yahoo Finance
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Hello Group Inc. Sponsored ADR (MOMO) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Teva Pharmaceutical ADR Gets Relative Strength Rating Upgrade - Inkl
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Why Sony Group Corporation (SONY) Is One of the Best ADR Stocks to Invest in? - Yahoo Finance
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
New Strong Buy Stocks for November 26th - Yahoo Finance
Why MINISO Group Holding Limited Unsponsored ADR (MNSO) Outpaced the Stock Market Today - Yahoo Finance
Petrobras to Distribute R$ 20 Billion in Dividends - Yahoo Finance
10 Stocks With the Largest Fair Value Estimate Increases After Q3 Earnings - Morningstar
Is Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Outperforming Other Consumer Discretionary Stocks This Year? - Yahoo Finance
Full Truck Alliance Co. Ltd. Sponsored ADR (YMM) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
XPeng Inc. Sponsored ADR (XPEV) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Sea Limited Q3 Earnings Miss Estimates, Shares Rise on Revenue Growth - Yahoo Finance
Such Is The Power Of CNH Industrial NV (NYSE: CNH) - Stocks Register
Hannover Rueck SE Reports Strong 2024 Earnings Growth - Yahoo Finance
11 New 4-Star Stocks - Morningstar
'This Is A New Teva,' Says CEO. But Investors Don't Seem To Believe. - Investor's Business Daily
XPeng Inc. Sponsored ADR (XPEV) Stock Moves -1.06%: What You Should Know - Yahoo Finance
Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sea Limited Sponsored ADR (SE) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Is Alstom (ALSMY) Outperforming Other Transportation Stocks This Year? - Yahoo Finance
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Germany Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Is EXL Service (EXLS) Stock Outpacing Its Business Services Peers This Year? - Yahoo Finance
Is DMARKET Electronic Services & Trading (HEPS) Outperforming Other Retail-Wholesale Stocks This Year? - Yahoo Finance
Is AllianceBernstein (AB) Stock Outpacing Its Finance Peers This Year? - Yahoo Finance
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.28 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Is American Outdoor Brands (AOUT) Outperforming Other Consumer Discretionary Stocks This Year? - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Monitoring Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insider movements - Knox Daily
Li Auto Inc. Sponsored ADR (LI) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News
Selling Buzz: Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial Daniell Richard sells 98,943 shares of the company – Knox Daily - Knox Daily
Qifu Technology Inc. ADR (QFIN) gets rating Initiated from Nomura - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 1.45 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.22%
0.82%
자본화:
|
볼륨(24시간):